| Literature DB >> 25430404 |
Mehmet Kadri Akboğa1, Ahmet Akyel, Asife Şahinarslan, Çağrı Yayla, Yakup Alsancak, Gökhan Gökalp, Serdar Nurkoç, Adnan Abacı.
Abstract
OBJECTIVE: The role of systemic and chronic inflammatory processes in the pathophysiology of rheumatic heart valve disease is well known. The neutrophil-to-lymphocyte ratio (NLR) was shown to be an indicator of systemic inflammation. In this study, we aimed to investigate relationship between NLR as a marker of systemic inflammation and rheumatic mitral valve stenosis (RMVS).Entities:
Mesh:
Substances:
Year: 2014 PMID: 25430404 PMCID: PMC5779174 DOI: 10.5152/akd.2014.5399
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Basal characteristics of groups
| Parameters | Control n=57 | RMVS n=314 | [ |
|---|---|---|---|
| Age, years | 50.2±14.2 | 49.2±13.0 | 0.60[ |
| Female, n (%) | 46 (80.7) | 235 (74.8) | 0.34 |
| Hypertension, n (%) | 25 (43.8) | 123 (39.1) | 0.59 |
| Diabetes mellitus, n (%) | 9 (15.7) | 43 (13.7) | 0.74 |
| Smoking, n (%) | 12 (21.6) | 43 (13.7) | 0.15 |
| CAD, n (%) | 11 (19.2) | 49 (15.5) | 0.46 |
| RAS blocker, n (%) | 24 (42.1) | 99 (31.6) | 0.15 |
| Diuretic, n (%) | 10 (17.5) | 90 (28.6) | 0.12 |
| CCB, n (%) | 8 (14.0) | 61 (19.5) | 0.36 |
| ß-blocker, n (%) | 14 (24.5) | 112 (35.6) | 0.11 |
| Statin, n (%) | 14 (24.5) | 54 (17.3) | 0.23 |
| Aspirin, n (%) | 18 (31.5) | 112 (35.6) | 0.51 |
| OAD, n (%) | 7 (12.2) | 40 (12.8) | 0.88 |
| Warfarin, n (%) | 0 (0) | 101 (32.2) | - |
| LVEF, % | 65.1±2.0 | 64.5±5.2 | 0.74 |
| LAD, cm | 33.9 (26-41) | 42.9 (30-62) | <0.001[ |
| LVEDD, cm | 46.3 (40-54) | 46.7 (34-59) | 0.34[ |
Data are given as mean±SD or %. CAD - coronary artery disease; CCB - calcium channel blocker; LAD - left atrial diameter; LVEDD - left ventricular end-diastolic diameter; LVEF - left ventricular ejection fraction; OAD - oral antidiabetic drug; RAS - renin-angiotensin system; RMVS - rheumatic mitral valve stenosis.
Chi-square test,
Student t-test,
Mann-Whitney U test
Laboratory parameters of the study groups
| Parameters | Control n=57 | RMVS n=314 | [ |
|---|---|---|---|
| Hemoglobin, g/dL | 13.6 (12.0-16.5) | 13.4 (12.0-16.5) | 0.38[ |
| Platelets, 103/mm3 | 246.7 (136-487) | 233.4 (110-503) | 0.20[ |
| Mean platelet volume, fL | 8.2±2.0 | 8.7±1.4 | 0.117 |
| White blood cell, 103/mm3 | 7.5 (3.1-11.4) | 7.6 (2.5-12.9) | 0.64[ |
| Neutrophils, 103/mm3 | 4.4 (1.4-7.7) | 4.7 (0.8-10.3) | 0.49[ |
| Lymphocytes, 103/mm3 | 2.2 (0.8-4.0) | 1.8 (0.4-4.6) | <0.001[ |
| Monocytes, 103/mm3 | 0.5±0.2 | 0.6±0.2 | 0.86 |
| NLR | 2.1 (0.7-5.8) | 2.9 (0.6-13.0) | <0.001[ |
| Creatinine, mg/dL | 0.77±0.2 | 0.79±0.2 | 0.29 |
| CRP mg/dL | 2.98 (0.6-6.3) | 5.99 (0.3-23.7) | 0.001[ |
| Total cholesterol, mg/dL | 196.2±38.2 | 188.0±36.1 | 0.16 |
| HDL-cholesterol, mg/dL | 47.9±11.3 | 45.4±10.5 | 0.12 |
| LDL-cholesterol, mg/dL | 122.9±32.8 | 116.3±28.0 | 0.17 |
| Triglyceride, mg/dL | 140.5±80.0 | 132.0±63.1 | 0.76 |
CRP- C-reactive protein; HDL - high-density lipoprotein; LDL - low-density lipoprotein; NLR - neutrophil-to- lymphocyte ratio; RMVS - rheumatic mitral valve stenosis.
Student t-test,
Mann-Whitney U test
Figure 1Neutrophil-to-lymphocyte ratio according to presence and severity of rheumatic mitral valve stenosis
†ANOVA followed by Tukey test
Multiple logistic regression analysis of rheumatic mitral valve stenosis
| Variable | [ | Odds ratio (95% CI) |
|---|---|---|
| Mean platelet volume | 0.29 | 0.81 (0.55-1.20) |
| Lymphocytes | 0.69 | 1.21 (0.47-3.12) |
| Neutrophil-to-lymphocyte ratio | 0.04 | 2.24 (1.03-4.86) |
| CRP | 0.03 | 1.34 (1.02-1.76) |
| LAD | 0.001 | 1.21 (1.08-1.36) |
CRP - C-reactive protein; LAD - left atrial diameter.
Multiple logistic regression analysis
Figure 2ROC curve analysis for neutrophil-to-lymphocyte ratio as a predictor of rheumatic mitral valve stenosis
†ROC analysis